Previous 10 | Next 10 |
Gainers: GeoVax Labs GOVX +39%. Entasis Therapeutics ETTX +21%. Allarity Therapeutics (ALLR) +14%. Tonix Pharmaceuticals (TNXP) +13%. TRxADE HEALTH (MEDS) +13%. Losers: Nymox Pharmaceutical NYMX -67%. Evoke Pharma EVOK -21%. NanoViricides...
3 Hot Biotech Penny Stocks to Add to Your Watchlist With the Market Down Recently, biotech penny stocks have seen heightened bullish sentiment. Today, the emphasis on biotech stocks comes as the Monkeypox virus is seeing a resurgence in certain areas around the world. Today, the WHO con...
Gainers: Leju Holdings Limited (LEJU) +47%. Redbox Entertainment (RDBX) +33%. SIGA Technologies (SIGA) +26%. Getnet (GET) +25%. Allarity (ALLR) +23%. NanoViricides (NNVC) +22%. Processa Pharmaceuticals (PCSA) +22%. TherapeuticsMD (TXMD) +17%. PyroGenesis Canada (PYR) +17%. Evofem Biosciences ...
The U.S. FDA had granted approval to a supplemental New Drug Application from TherapeuticsMD (NASDAQ:TXMD) for its Annovera birth control ring. Shares are up 25% in Friday morning trading. The company said that the approval should lead to fewer batch rejections and increase future p...
- ANNOVERA is the only FDA-approved procedure-free, long-lasting, reversible birth control - - With this approval, the Company expects a significant reduction in its manufacturing batch rejections and an increase in future product supply and will enable the Company to better meet sh...
Gainers: Scholar Rock (SRRK) +26%. Phathom Pharmaceuticals (PHAT) +12%. 4d Pharma (LBPS) +10%. Ocular Therapeutix (OCUL) +9%. Magenta Therapeutics (MGTA) +8%. Losers: PolarityTE (PTE) -34%. Tonix Pharmaceuticals (TNXP) -22%. Albireo Pharma (ALBO) ...
Image source: The Motley Fool. TherapeuticsMD, Inc. (NASDAQ: TXMD) Q1 2022 Earnings Call May 16, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: TherapeuticsMD, Inc. (TXMD) Q1 2022 Earnings Call Transcript
TherapeuticsMD (NASDAQ:TXMD) saw its Q1 2022 net loss widen 24% to $49M (-$5.69 basic and diluted share) compared to the prior-year period weighed down by a $8.4M loss on extinguishment of debt The net loss was a miss while revenue of ~$19.3M, around a 3% year-over-year-decline, was a beat. T...
Therapeutics MD press release (NASDAQ:TXMD): Q1 GAAP EPS of -$5.69 misses by $1.69. Revenue of $19.34M (-2.7% Y/Y) beats by $1.39M. For further details see: Therapeutics MD GAAP EPS of -$5.69 misses by $1.69, revenue of $19.34M beats by $1.39M
- Quarterly total net product revenue of $19.3 million - - ANNOVERA® TRx of 8,014, an increase of 27% over Q1 2021 - - Announced and completed vitaCare divestiture in five weeks - - Conference call scheduled for 4:30 p.m. ET today - TherapeuticsMD, Inc. (“TXMD&...
News, Short Squeeze, Breakout and More Instantly...
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Net Income (...
• Evaluation of strategic alternatives continues TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023...